#VisualAbstract: Risankizumab was Non-Inferior to Ustekinumab for the Clinical Remission of Moderate-to-Severe Crohn’s Disease
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: moderate-to-severe Crohn’s disease
Upadacitinib therapy effective at inducing remission in Crohn’s disease
1. In this randomized controlled trial, upadacitinib resulted in higher remission rates for patients with Crohn’s disease compared to a ...